The effect of maintenance hormone therapy on overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study. This is an ASCO Meeting Abstract from the ...
A characteristic of tumors includes the ability to avoid the immune system. In many cases tumors can progress without detection of immune cells. In the literature many scientists refer to undetectable ...
CD47-null femoral fractures show reduced bone formation, but increased tissue mineral density. µCT analysis of transverse femoral fracture in WT (n = 9) and CD47-null (n = 11-14) mice at 10- and ...
“Together, these findings support a beneficial role for CD47 knockdown in alleviating age-associated metabolic dysfunction through coordinated effects across multiple organs” “Together, these findings ...
Retrospective study findings show that CD47 expression on Hodgkin and Reed–Sternberg (HRS) cells varied between patients who had classical Hodgkin lymphoma (HL) and was associated with poor outcomes.
Risk of myelodysplastic syndrome and myeloproliferative neoplasms in patients with stable coronary artery disease and autoimmune conditions treated with colchicine. This is an ASCO Meeting Abstract ...
SEOUL, South Korea--(BUSINESS WIRE)--ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 1a solid tumour clinical trial (IMC-002-K102 Study) of IMC-002, a CD47 monoclonal antibody, at ...
A new research paper was published in Volume 17, Issue 12 of Aging-US on December 1, 2025, titled “CD47 antisense oligonucleotide treatment improves glucose homeostasis and alleviates dyslipidemia in ...
Liminatus Pharma is a preclinical oncology company focused on a CD47 antibody, with no clinical pipeline and years away from human trials. CD47-targeting drugs have a track record of failure, making ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results